Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) FCF Margin: 2020-2025

Historic FCF Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -43.42%.

  • Maravai Lifesciences Holdings' FCF Margin fell 5001.00% to -43.42% in Q3 2025 from the same period last year, while for Sep 2025 it was -34.47%, marking a year-over-year decrease of 3060.00%. This contributed to the annual value of -8.56% for FY2024, which is 2956.00% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' FCF Margin stood at -43.42%, which was down 56.63% from -27.72% recorded in Q2 2025.
  • Maravai Lifesciences Holdings' FCF Margin's 5-year high stood at 97.70% during Q1 2023, with a 5-year trough of -43.42% in Q3 2025.
  • Over the past 3 years, Maravai Lifesciences Holdings' median FCF Margin value was -12.15% (recorded in 2023), while the average stood at -6.19%.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' FCF Margin soared by 5,587bps in 2021, and later slumped by 11,972bps in 2024.
  • Maravai Lifesciences Holdings' FCF Margin (Quarterly) stood at 23.24% in 2021, then soared by 2,225bps to 45.49% in 2022, then crashed by 5,764bps to -12.15% in 2023, then slumped by 2,407bps to -36.22% in 2024, then crashed by 5,001bps to -43.42% in 2025.
  • Its FCF Margin was -43.42% in Q3 2025, compared to -27.72% in Q2 2025 and -31.22% in Q1 2025.